It’s amazing the strides in predicting who will and who will not respond to a certain type of drug for treatment of many conditions including hepatitis C. You have probably heard about a variation in IL28B gene that has been found to greatly increase the chances of responding to current HCV current therapy. This test indicates that people have a two-fold increased chance of responding to HCV therapy compared to those who do not have this gene variation. The test for this marker is expected to be commercially available in the next month or so. I wrote a recap of the studies about IL28B that will we will publish in the August HCV Advocate Newsletter. This marker will be a great tool in the treatment decision process.